The purpose of this study is to determine the safety and feasibility of using intra-arterial Tenecteplase in patients undergoing blood clot extraction for treatment of acute ischemic (non-bleeding) stroke. Intravenous Tenecteplase is FDA-approved to treat patients with an ischemic stroke presenting within the 0-3-hour time window.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Participants with Change in Symptomatic Intracranial Hemorrhage
Timeframe: Hour 36
Participants with Parenchymal Hematoma Type 1
Timeframe: 24 Hours
Participants with Parenchymal Hematoma Type 2
Timeframe: 24 Hours
30-Day Mortality Count
Timeframe: Day 30
90-Day Mortality Count
Timeframe: Day 90
Number of Grade 3 Adverse Events
Timeframe: Hour 24
Number of Grade 3 Adverse Events
Timeframe: Day 5
Number of Grade 3 Adverse Events
Timeframe: Day 30
Number of Grade 3 Adverse Events
Timeframe: Day 90